Dendritic cell-Natural Killer cell-Tumor Cell Interface (DC-NK-Tumor Interface)

The Dendritic cell-Natural Killer cell-Tumor Cell Interface represents the complex multicellular interaction and signaling network that occurs between innate immune cells and malignant cells within the tumor microenvironment [1]. This interface is characterized by a bidirectional "crosstalk" where Natural Killer (NK) cells promote the maturation and antigen cross-presentation capabilities of Dendritic Cells (DCs) through the release of IFN-gamma and TNF-alpha [2, 3]. Reciprocally, activated DCs sustain NK cell survival and cytotoxic activity through the production of stimulatory cytokines such as IL-12, IL-15, and IL-18 [3, 6]. Tumor cells interact with this axis by presenting ligands like MICA/B or B7-H6 that trigger NK cell-mediated lysis, but they also employ immunosuppressive mechanisms like TGF-beta secretion to disrupt the interface and evade detection [3, 8]. Therapeutic targeting of this interface often involves monoclonal antibodies that induce antibody-dependent cellular cytotoxicity (ADCC), effectively bridging NK and DC responses to trigger downstream adaptive immunity [1, 5]. Modern strategies, including the use of immune checkpoint inhibitors and cytokine agonists, aim to restore the synergistic activation of the DC-NK axis to overcome the immunosuppressive nature of the tumor microenvironment [6, 10].

Other names

DC-NK crosstalkDC-NK-tumor cell axisNK-DC-tumor synapseNK-DC interactions in cancerInnate immune crosstalk microenvironment

Modulation of the bidirectional activation axis between innate immune cells and tumor ligands to enhance antigen cross-presentation, trigger antibody-dependent cellular cytotoxicity (ADCC), and reverse immune checkpoint-mediated suppression.